公开(公告)号：US09410154B2

公开(公告)日：2016-08-09

申请号：US14731824

申请日：2015-06-05

申请人： BENITEC BIOPHARMA LIMITED

发明人： Michael Wayne Graham ,  Peter French ,  York YuanYuan Zhu ,  YiXiang Lu ,  TieJun Li ,  YunCheng Sun ,  XiaoJun Tang ,  Li Shan

IPC分类号： C07H21/04 ,  C12N15/113

CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2310/531

摘要： RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

公开(公告)号：US20150344885A1

公开(公告)日：2015-12-03

申请号：US14731824

申请日：2015-06-05

申请人： BENITEC BIOPHARMA LIMITED

发明人： Michael Wayne Graham ,  Peter French ,  York YuanYuan Zhu ,  YiXiang Lu ,  TieJun Li ,  YunCheng Sun ,  XiaoJun Tang ,  Li Shan

IPC分类号： C12N15/113

CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2310/531

摘要： RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

摘要翻译： 提供RNA干扰（RNAi）试剂和使用RNAi试剂治疗个体中的乙型肝炎感染，以及含有RNAi试剂的药物组合物。 用于表达它们的RNAi剂或构建体用于抑制至少一种乙型肝炎病毒（HBV）基因的表达，其中每种试剂包含与从靶区转录的预测序列互补或基本上互补的效应序列。 在本发明的一些实施方案中，所述试剂具有多于一个效应序列; 其中所述多个效应子可以靶向相同基因和/或不同HBV基因的HBV基因的相同区域，不同（可能重叠的）区域。

公开(公告)号：US09790502B2

公开(公告)日：2017-10-17

申请号：US15206948

申请日：2016-07-11

申请人： BENITEC BIOPHARMA LIMITED

发明人： Michael Wayne Graham ,  Peter French ,  York YuanYuan Zhu ,  YiXiang Lu ,  TieJun Li ,  YunCheng Sun ,  XiaoJun Tang ,  Li Shan

IPC分类号： C07H21/04 ,  C12N15/113

CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2310/531

摘要： This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

公开(公告)号：US20170002356A1

公开(公告)日：2017-01-05

申请号：US15206948

申请日：2016-07-11

申请人： BENITEC BIOPHARMA LIMITED

发明人： Michael Wayne Graham ,  Peter French ,  York YuanYuan Zhu ,  YiXiang Lu ,  TieJun Li ,  YunCheng Sun ,  XiaoJun Tang ,  Li Shan

IPC分类号： C12N15/113

CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2310/531

摘要： This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilised to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

摘要翻译： 本发明涉及RNA干扰（RNAi）试剂以及该RNAi试剂在个体中治疗乙型肝炎感染的用途，以及含有本发明RNAi试剂的药物组合物。 用于表达它们的RNAi试剂或构建体用于抑制至少一种乙型肝炎病毒（HBV）基因的表达，其中该试剂包含与从靶区域转录的预测序列互补或基本上互补的效应序列。 在本发明的一些形式中，所述试剂具有多于一个效应序列。 多个效应子可以靶向相同基因和/或不同HBV基因的HBV基因的相同区域，不同（可能重叠的）区域。